Breaking News Instant updates and real-time market news.

2022-05-04 08:54:18 NMM Navios Maritime Partners $31.14 / +1.13 (+3.77%) 08:54 05/04/22 05/04 08:54 05/04/22 08:54	Navios Maritime Partners to acquire four newbuilding vessels for $58.5M each Navios Maritime Partners announced that it agreed to purchase four 115,000 dwt LR2 newbuilding vessels, for a purchase price of $58.5 million each plus $4.2 million in additional features/improvements. The vessels have been designed with the latest technology to optimize efficiency. They are expected to be delivered into Navios Partners' fleet during 2024 and first quarter of 2025. The closing of the transaction is subject to completion of customary documentation. The two 115,000 dwt LR2 newbuilding vessels expected to be delivered in 2024, have been chartered-out for an average period of 60 months, at a net rate of $25,576 per day to an investment grade charterer. The charterer has an option to extend the charter for a further five one-year options at rates increasing by $1,234 per day each year. In addition, the Charterer has the option to charter one or both of the two additional tanker vessels on identical terms. The option can be exercised by mid October 2022.

2022-05-04 08:54:18

NMM

Navios Maritime Partners

$31.14 / +1.13 (+3.77%)

08:54

05/04/22

05/04

08:54

05/04/22

08:54

Navios Maritime Partners to acquire four newbuilding vessels for $58.5M each

Navios Maritime Partners announced that it agreed to purchase four 115,000 dwt LR2 newbuilding vessels, for a purchase price of $58.5 million each plus $4.2 million in additional features/improvements. The vessels have been designed with the latest technology to optimize efficiency. They are expected to be delivered into Navios Partners' fleet during 2024 and first quarter of 2025. The closing of the transaction is subject to completion of customary documentation. The two 115,000 dwt LR2 newbuilding vessels expected to be delivered in 2024, have been chartered-out for an average period of 60 months, at a net rate of $25,576 per day to an investment grade charterer. The charterer has an option to extend the charter for a further five one-year options at rates increasing by $1,234 per day each year. In addition, the Charterer has the option to charter one or both of the two additional tanker vessels on identical terms. The option can be exercised by mid October 2022.

OTHER BREAKING NEWS FROM THE FLY

Initiation	Oak Street Health resumed with an Outperform at Bernstein » 20:20 05/26/22 05/26 20:20 05/26/22 20:20 OSH Oak Street Health $18.29 / +0.87 (+4.99%) Bernstein analyst Lance… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options OSH Oak Street Health $18.29 / +0.87 (+4.99%) 03/01/22 Oak Street Health rises 25.6% 03/01/22 Oak Street Health rises 17.2% 12/29/21 Oak Street Health says COO Geoff Price will transition to CIO OSH Oak Street Health $18.29 / +0.87 (+4.99%) 16:12 Today Stifel Oak Street Health initiated with a Buy at Stifel 04/20/22 UBS Oak Street Health initiated with a Neutral at UBS 04/19/22 Barclays Oak Street Health price target raised to $31 from $27 at Barclays 03/29/22 Guggenheim Oak Street Health initiated with a Neutral at Guggenheim OSH Oak Street Health $18.29 / +0.87 (+4.99%) 05/03/22 Oak Street Health sees FY22 revenue $2.1B-$2.135B, consensus $2.13B 05/03/22 Oak Street Health sees Q2 revenue $517.5M-$522.5M, consensus $523.88M 05/03/22 Oak Street Health reports Q1 EPS (43c), consensus (39c) 02/28/22 Oak Street Health sees FY22 revenue $2.1B-$2.135B, consensus $2.27B 27 May OSH Oak Street Health $18.29 / +0.87 (+4.99%) 04/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/29/21 Fly Intel: Pre-market Movers OSH Oak Street Health $18.29 / +0.87 (+4.99%) 02/28/22 Oak Street Health options imply 19.8% move in share price post-earnings 02/25/22 Oak Street Health put volume heavy and directionally bearish
Downgrade	UnitedHealth downgraded to Market Perform at Bernstein on valuation » 20:16 05/26/22 05/26 20:16 05/26/22 20:16 UNH UnitedHealth $502.40 / +4.29 (+0.86%) Bernstein analyst Lance… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options UNH UnitedHealth $502.40 / +4.29 (+0.86%) 05/16/22 Soros Capital buys Suncor and Mosaic during Q1, exits Alphabet 05/16/22 Lone Pine adds TSMC in Q1, exits KE Holdings and Adobe 05/12/22 UnitedHealth selected by State of Missouri to serve Medicaid beneficiaries 04/26/22 Change says UnitedHealth to sell ClaimsXten for $2.2B if deal closes UNH UnitedHealth $502.40 / +4.29 (+0.86%) 16:45 Today Bernstein UnitedHealth downgraded to Market Perform from Outperform at Bernstein 05/11/22 Citi MultiPlan price target raised to $6.50 from $6 at Citi 04/26/22 Piper Sandler Piper 'incrementally confident' Change, UNH will prevail in August 04/25/22 Deutsche Bank LHC Group downgraded to Hold from Buy at Deutsche Bank UNH UnitedHealth $502.40 / +4.29 (+0.86%) 04/14/22 UnitedHealth raises FY22 adjusted EPS view to $21.20-$21.70 from $21.10-$21.60 04/14/22 UnitedHealth reports Q1 adjusted EPS $5.49, consensus $5.38 04/13/22 Notable companies reporting before tomorrow's open 04/13/22 Notable companies reporting before tomorrow's open UNH UnitedHealth $502.40 / +4.29 (+0.86%) 05/20/22 UnitedHealth focuses on telehealth to reduce costs, WSJ reports 04/04/22 Change Healthcare in talks to sell ClaimsXten business, Bloomberg says 03/24/22 UnitedHealth's Optum bought Refresh Mental Health from PE owner, Axios reports 02/24/22 UnitedHealth plans to challenge DOJ's lawsuit, Reuters reports UNH UnitedHealth $502.40 / +4.29 (+0.86%) 05/20/22 What You Missed On Wall Street On Friday 05/20/22 What You Missed On Wall Street This Morning 04/14/22 What You Missed On Wall Street On Thursday 04/14/22 What You Missed On Wall Street This Morning 07/15/22 UnitedHealth - UNH 06/06/22 UnitedHealth Group UNH UnitedHealth $502.40 / +4.29 (+0.86%) 03/14/22 UnitedHealth put volume heavy and directionally bearish
Initiation	Humana resumed with a Market Perform at Bernstein » 20:12 05/26/22 05/26 20:12 05/26/22 20:12 HUM Humana $452.22 / +7.33 (+1.65%) Bernstein analyst Lance… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options HUM Humana $452.22 / +7.33 (+1.65%) 05/13/22 Starboard takes stake in Humana, exits System1 05/03/22 Kala announces new commercial, Medicare coverage for EYSUVIS 04/21/22 Humana to divest interest in Hospice, Personal Care divisions of KAH Hospice 02/22/22 Humana to add two new independent directors in Starboard cooperation agreement HUM Humana $452.22 / +7.33 (+1.65%) 04/28/22 Wells Fargo Humana price target raised to $512 from $491 at Wells Fargo 04/13/22 UBS Humana upgraded to Buy from Neutral at UBS 04/07/22 Truist Humana price target raised to $490 from $460 at Truist 02/03/22 Deutsche Bank Humana price target raised to $435 from $418 at Deutsche Bank HUM Humana $452.22 / +7.33 (+1.65%) 04/27/22 Humana raises FY22 adjusted EPS view to 'approximately $24.50' 04/27/22 Humana reports Q1 adjusted EPS $8.04, consensus $6.78 02/02/22 Humana sees FY22 adjusted EPS at least $24.00, consensus $23.85 02/02/22 Humana reports Q4 adjusted EPS $1.24, consensus $1.15 HUM Humana $452.22 / +7.33 (+1.65%) 04/21/22 Humana in talks to sell arm of its Kindred at Home to CD&R, Bloomberg reports 01/11/22 Insurers to cover rapid Covid-19 tests under White House plan, WSJ reports HUM Humana $452.22 / +7.33 (+1.65%) 04/13/22 What You Missed On Wall Street On Wednesday 04/13/22 What You Missed On Wall Street This Morning 04/13/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/03/22 Wall Street in Fives - Must Read Lists for Thursday HUM Humana $452.22 / +7.33 (+1.65%) 02/03/22 Early notable gainers among liquid option names on February 3rd 01/12/22 Unusually active option classes on open January 12th
Upgrade	HCA Healthcare upgraded to Outperform from Market Perform at Bernstein » 20:10 05/26/22 05/26 20:10 05/26/22 20:10 HCA HCA Healthcare $211.86 / +6.12 (+2.97%) Bernstein analyst Lance… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly HCA HCA Healthcare $211.86 / +6.12 (+2.97%) 05/17/22 HCA Healthcare chief HR officer Berres sells 2,358 common shares 04/22/22 HCA Healthcare falls -18.2% 04/22/22 HCA Healthcare falls -13.4% 02/14/22 Appaloosa takes stake in General Motors, exits position in HCA Healthcare HCA HCA Healthcare $211.86 / +6.12 (+2.97%) 16:53 Today Bernstein HCA Healthcare upgraded to Outperform from Market Perform at Bernstein 05/03/22 Mizuho HCA Healthcare price target lowered to $260 from $290 at Mizuho 04/26/22 BMO Capital HCA Healthcare price target lowered to $240 from $275 at BMO Capital 04/26/22 UBS HCA Healthcare price target lowered to $241 from $289 at UBS HCA HCA Healthcare $211.86 / +6.12 (+2.97%) 04/22/22 HCA Healthcare cuts FY22 EPS view to $16.40-$17.60 from $18.40-$19.20 04/22/22 HCA Healthcare reports Q1 EPS $4.14, consensus $4.25 01/27/22 HCA Healthcare sees FY22 EPS $18.40-$19.20, consensus $18.73 01/27/22 HCA Healthcare reports Q4 EPS $5.75, consensus $4.53 HCA HCA Healthcare $211.86 / +6.12 (+2.97%) 04/22/22 What You Missed On Wall Street On Friday 04/22/22 What You Missed On Wall Street This Morning 04/22/22 Fly Intel: Pre-market Movers 01/27/22 Wall Street in Fives - Must Read Lists for Thursday
Hot Stocks	Cathay General adopts new buyback program for up to $125M » 20:04 05/26/22 05/26 20:04 05/26/22 20:04 CATY Cathay General $40.00 / +0.965 (+2.47%) Cathay General… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings On The Fly CATY Cathay General $40.00 / +0.965 (+2.47%) 01/31/22 Wedbush Cathay General price target raised to $55 from $50 at Wedbush 08/30/21 Truist Cathay General price target raised to $44 from $40 at Truist 06/21/21 Truist Cathay General assumed with a Hold at Truist CATY Cathay General $40.00 / +0.965 (+2.47%) 04/25/22 Cathay General reports Q1 EPS 99c, consensus 91c 01/27/22 Cathay General reports Q4 EPS 98c, consensus 92c CATY Cathay General $40.00 / +0.965 (+2.47%) 04/25/22 Fly Intel: After-Hours Movers

Downgrade	CVS Health downgraded to Market Perform from Outperform at Bernstein » 20:03 05/26/22 05/26 20:03 05/26/22 20:03 CVS CVS Health $97.80 / +0.68 (+0.70%) Bernstein analyst Lance… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options CVS CVS Health $97.80 / +0.68 (+0.70%) 05/09/22 Aris Water Solutions reaches water management pact with Chevron 05/04/22 CVS Health reports 98% core client retention for 2023 selling season 05/04/22 CVS Health says entered 2022 with 'significant momentum' across the business 04/26/22 Predictive Oncology appoints Theresa Ferguson as senior director, marketing CVS CVS Health $97.80 / +0.68 (+0.70%) 16:45 Today Bernstein CVS Health downgraded to Market Perform from Outperform at Bernstein 09:42 Today Oppenheimer Oppenheimer continues to favor Teladoc, new policies positive for telehealth 05/05/22 Deutsche Bank CVS Health price target raised to $113 from $110 at Deutsche Bank 04/25/22 Craig-Hallum Identiv initiated with a Buy at Craig-Hallum CVS CVS Health $97.80 / +0.68 (+0.70%) 05/04/22 CVS Health raises FY22 Health Care benefits revenue view to $89.3B-$90.8B 05/04/22 CVS Health raises FY22 revenue view to $305B-$310B from $304B-$309B 05/04/22 CVS Health raises FY22 adjusted EPS view to $8.20-$8.40 from $8.10-$8.30 05/04/22 CVS Health reports Q1 adjusted EPS $2.22, consensus $2.15 CVS CVS Health $97.80 / +0.68 (+0.70%) 05/25/22 CVS to stop filling controlled substance prescriptions for Cerebral, WSJ reports 04/23/22 Merck, CVS among dividend stocks to help whip inflation now, Barron's says 03/11/22 CVS CEO removing several executives after probe of complaint handling, WSJ says 03/02/22 CVS, Walgreens, Walmart participating in test-to-treat program, MarketWatch says CVS CVS Health $97.80 / +0.68 (+0.70%) 05/04/22 What You Missed On Wall Street On Wednesday 05/04/22 What You Missed On Wall Street This Morning 05/04/22 Fly Intel: Pre-market Movers 03/29/22 What You Missed On Wall Street On Tuesday 06/10/22 CVS Health - CVS 08/03/22 CVS Health - CVS CVS CVS Health $97.80 / +0.68 (+0.70%) 05/04/22 Unusually active option classes on open May 4th 05/02/22 Unusually active option classes on open May 2nd 04/26/22 CVS Health call volume above normal and directionally bullish 04/06/22 CVS Health call volume above normal and directionally bullish
Initiation	Cigna resumed with a Market Perform at Bernstein » 19:59 05/26/22 05/26 19:59 05/26/22 19:59 CI Cigna $268.88 / +3.04 (+1.14%) Bernstein analyst Lance… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options CI Cigna $268.88 / +3.04 (+1.14%) 05/02/22 Bioventus agrees to nationwide contract with Cigna for DUROLANE, GELSYN-3 03/08/22 Kala Pharmaceuticals announces EYSUVIS now covered by UnitedHealthcare, Cigna 02/28/22 Cigna to increase share repurchase authorization by $6B 02/18/22 Cigna CHRO John Murabito to retire, Cynthia Ryan to succeed CI Cigna $268.88 / +3.04 (+1.14%) 06:05 Today BofA Cigna upgraded to Neutral from Underperform at BofA 05/23/22 Barclays Cigna price target raised to $310 from $275 at Barclays 05/16/22 JPMorgan Cigna upgraded to Overweight from Neutral at JPMorgan 05/10/22 Raymond James Cigna price target raised to $300 from $275 at Raymond James CI Cigna $268.88 / +3.04 (+1.14%) 05/06/22 Cigna raises FY22 adjusted EPS view to at least $22.60 from at least $22.40 05/06/22 Cigna reports Q1 adjusted EPS $6.01, consensus $5.18 05/05/22 Notable companies reporting before tomorrow's open 05/05/22 Notable companies reporting before tomorrow's open CI Cigna $268.88 / +3.04 (+1.14%) 01/26/22 Centene attracted acquisition interest from Cigna recently, Bloomberg says 01/26/22 Centene draws takeover interest from Cigna in recent months, Bloomberg says 01/11/22 Insurers to cover rapid Covid-19 tests under White House plan, WSJ reports CI Cigna $268.88 / +3.04 (+1.14%) 10:11 Today Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/16/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/09/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/06/22 What You Missed On Wall Street On Friday 06/17/22 Cigna - CI 08/04/22 Cigna - CI CI Cigna $268.88 / +3.04 (+1.14%) 05/06/22 Early notable gainers among liquid option names on May 6th
Initiation	Centene resumed with an Outperform at Bernstein » 19:58 05/26/22 05/26 19:58 05/26/22 19:58 CNC Centene $81.77 / -3.53 (-4.14%) Bernstein analyst Lance… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options CNC Centene $81.77 / -3.53 (-4.14%) 05/10/22 Centene, Behavioral Health Center of Excellence enter partnership 05/05/22 Centene divests two pharmacy businesses for total proceeds of $2.8B 04/05/22 Skylight Health, Collaborative Health announce joint venture partnership 03/28/22 Cirrus Logic announces Denise Grode as chief human resources officer CNC Centene $81.77 / -3.53 (-4.14%) 06:07 Today BofA Centene downgraded to Neutral from Buy at BofA 03/29/22 Deutsche Bank CVS Health downgraded to Hold from Buy at Deutsche Bank 03/23/22 BTIG Exagen price target lowered to $15 from $20 at BTIG 03/23/22 Jefferies Centene CEO pick may spur some negative stock reaction, says Jefferies CNC Centene $81.77 / -3.53 (-4.14%) 04/26/22 Centene raises FY22 adjusted EPS view to $5.40-$5.55 from $5.30-$5.50 04/26/22 Centene reports Q1 adjusted EPS $1.83, consensus $1.68 04/25/22 Notable companies reporting before tomorrow's open 04/25/22 Notable companies reporting before tomorrow's open CNC Centene $81.77 / -3.53 (-4.14%) 02/04/22 California signs secret Medicaid deal with Kaiser Permanente, KHN reports 01/26/22 Centene attracted acquisition interest from Cigna recently, Bloomberg says 01/26/22 Centene draws takeover interest from Cigna in recent months, Bloomberg says 01/11/22 Insurers to cover rapid Covid-19 tests under White House plan, WSJ reports CNC Centene $81.77 / -3.53 (-4.14%) 16:28 Today What You Missed On Wall Street On Thursday 12:27 Today What You Missed On Wall Street This Morning 10:11 Today Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/05/22 What You Missed On Wall Street On Thursday CNC Centene $81.77 / -3.53 (-4.14%) 01/06/22 Centene put volume heavy and directionally bearish 12/15/21 Centene call volume above normal and directionally bullish 12/14/21 Early notable gainers among liquid option names on December 14th 12/10/21 Early notable gainers among liquid option names on December 10th
Initiation	Anthem resumed with an Outperform at Bernstein » 19:57 05/26/22 05/26 19:57 05/26/22 19:57 ANTM Anthem $512.85 / +7.665 (+1.52%) Bernstein analyst Lance… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly ANTM Anthem $512.85 / +7.665 (+1.52%) 04/20/22 Anthem: Medical enrollment totaled 46.8M members at March 31 03/10/22 Anthem announces intent to change name to Elevance Health 02/03/22 CMS releases 2023 Medicare Advantage, Part D advance notice 01/26/22 Anthem sees FY22 medical membership 45.6M-46.2M ANTM Anthem $512.85 / +7.665 (+1.52%) 05/25/22 Wells Fargo Anthem price target lowered to $580 from $586 at Wells Fargo 05/04/22 Mizuho Anthem price target raised to $545 from $510 at Mizuho 04/25/22 BMO Capital Anthem price target raised to $625 from $540 at BMO Capital 04/22/22 Wells Fargo Anthem price target raised to $586 at Wells Fargo ANTM Anthem $512.85 / +7.665 (+1.52%) 04/20/22 Anthem now sees FY22 adjusted EPS greater than $28.40, consensus $28.48 04/20/22 Anthem reports Q1 adjusted EPS $8.25, consensus $7.81 03/08/22 Anthem backs FY22 adjusted EPS view greater than $28.25, consensus $28.47 01/26/22 Anthem sees FY22 adjusted EPS greater than $28.25, consensus $28.66 ANTM Anthem $512.85 / +7.665 (+1.52%) 03/10/22 Anthem plans name change to Elevance Health, WSJ reports 02/04/22 California signs secret Medicaid deal with Kaiser Permanente, KHN reports 01/11/22 Insurers to cover rapid Covid-19 tests under White House plan, WSJ reports ANTM Anthem $512.85 / +7.665 (+1.52%) 04/20/22 What You Missed On Wall Street On Wednesday 04/20/22 What You Missed On Wall Street This Morning 04/20/22 Fly Intel: Pre-market Movers 02/03/22 Wall Street in Fives - Must Read Lists for Thursday
Hot Stocks	Avis Budget chairman buys $4.9M in common stock » 19:13 05/26/22 05/26 19:13 05/26/22 19:13 CAR Avis Budget $185.03 / +6.06 (+3.39%) In a regulatory filing,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options CAR Avis Budget $185.03 / +6.06 (+3.39%) 05/02/22 Avis Budget jumps 9% to $305.00 after Q1 results beat estimates CAR Avis Budget $185.03 / +6.06 (+3.39%) 05/04/22 Deutsche Bank Avis Budget price target raised to $238 from $193 at Deutsche Bank 04/26/22 Deutsche Bank Hertz named short-term buy idea at Deutsche Bank 04/20/22 Barclays Barclays upgrades Avis to neutral on 'constructive' rental stance 04/20/22 Barclays Avis Budget upgraded to Equal Weight from Underweight at Barclays CAR Avis Budget $185.03 / +6.06 (+3.39%) 05/02/22 Avis Budget reports Q1 adjusted EPS $9.99, consensus $3.45 02/14/22 Avis Budget reports Q4 adjusted EPS $7.08, consensus $6.15 CAR Avis Budget $185.03 / +6.06 (+3.39%) 02/24/22 Car rental companies expect shortages to continue, WSJ reports CAR Avis Budget $185.03 / +6.06 (+3.39%) 05/03/22 Fly Intel: Pre-market Movers 05/02/22 Fly Intel: After-Hours Movers 04/20/22 What You Missed On Wall Street On Wednesday 04/20/22 What You Missed On Wall Street This Morning CAR Avis Budget $185.03 / +6.06 (+3.39%) 05/20/22 Avis Budget put volume heavy and directionally bearish 05/02/22 Avis Budget options imply 15.7% move in share price post-earnings 02/14/22 Avis Budget options imply 19.8% move in share price post-earnings

Hot Stocks	Myriad Genetics to present multiple genetic studies in cancer treatment at ASCO » 19:04 05/26/22 05/26 19:04 05/26/22 19:04 MYGN Myriad Genetics $21.15 / -0.05 (-0.24%) The company states:… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Events MYGN Myriad Genetics $21.15 / -0.05 (-0.24%) 05/03/22 Myriad expands partnership with Intermountain Precision Genomics 04/26/22 Myriad Genetics report results on nationwide survey 03/14/22 Myriad Genetics launches Precise Oncology Solutions offering 12/14/21 Myriad Genetics promotes Nicole Lambert to COO MYGN Myriad Genetics $21.15 / -0.05 (-0.24%) 10/14/21 Cowen Myriad Genetics coverage transferred at Cowen 06/15/21 Fly Intel: Top five analyst initiations 06/15/21 Raymond James Myriad Genetics initiated with a Market Perform at Raymond James 06/03/21 Goldman Sachs Myriad Genetics initiated with a Sell at Goldman Sachs MYGN Myriad Genetics $21.15 / -0.05 (-0.24%) 05/05/22 Myriad Genetics sees 2022 adjusted EPS 0c-20c, consensus 8c 05/05/22 Myriad Genetics reports Q1 adjusted EPS (3c), consensus (7c) 02/24/22 Myriad Genetics sees 2020 adjusted EPS $0-20c, consensus 15c 02/24/22 Myriad Genetics reports Q4 adjusted EPS (2c), consensus (2c) MYGN Myriad Genetics $21.15 / -0.05 (-0.24%) 01/03/22 NY Times investigation finds 85% of positive results from NIPTs are incorrect 06/02/22 Myriad Genetics Inc.
Earnings	Taro Pharmaceutical reports Q4 EPS 73c vs. (78c) last year » 19:01 05/26/22 05/26 19:01 05/26/22 19:01 TARO Taro Pharmaceutical $34.54 / -2.25 (-6.12%) Reports Q4 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research TARO Taro Pharmaceutical $34.54 / -2.25 (-6.12%) 02/22/22 Taro Pharmaceutical to acquire Alchemee, terms undisclosed 12/01/21 Taro Pharmaceutical appoints William Coote CFO TARO Taro Pharmaceutical $34.54 / -2.25 (-6.12%) 01/31/22 H.C. Wainwright Taro Pharmaceutical price target lowered to $73 from $75 at H.C. Wainwright 01/18/22 H.C. Wainwright Taro Pharmaceutical price target lowered to $75 from $82 at H.C. Wainwright 07/28/21 H.C. Wainwright Taro Pharmaceutical price target raised to $82 from $80 at H.C. Wainwright
Hot Stocks	Biomea Fusion to present new preclinical data on BMF-219 at ASCO » 19:00 05/26/22 05/26 19:00 05/26/22 19:00 BMEA Biomea Fusion $5.20 / +0.03 (+0.58%) Biomea Fusion… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options BMEA Biomea Fusion $5.20 / +0.03 (+0.58%) 05/19/22 Biomea Fusion announces nomination of BMF-500 as IND candidate 04/08/22 Biomea Fusion: BMF-219 showed strong cytotoxic activity in trial 02/01/22 Biomea Fusion appoints Steve Morris as Chief Medical Officer 01/25/22 Biomea Fusion doses first patient in Phase I trial of BMF-219 BMEA Biomea Fusion $5.20 / +0.03 (+0.58%) 05/17/22 Piper Sandler Biomea Fusion price target lowered to $25 from $27 at Piper Sandler 01/12/22 H.C. Wainwright Biomea Fusion initiated with a Buy at H.C. Wainwright 12/16/21 Oppenheimer Biomea Fusion initiated with an Outperform at Oppenheimer BMEA Biomea Fusion $5.20 / +0.03 (+0.58%) 05/16/22 Biomea Fusion reports Q1 EPS (56c), consensus (53c) 02/28/22 Biomea Fusion reports Q4 EPS (51c), consensus (45c) 06/13/22 Biomea Fusion 06/22/22 BioMea Fusion, Inc. BMEA Biomea Fusion $5.20 / +0.03 (+0.58%) 03/09/22 Twenty new option listings and one option delisting on March 9th
Recommendations	Equinix price target lowered to $770 from $825 at BMO Capital » 18:57 05/26/22 05/26 18:57 05/26/22 18:57 EQIX Equinix $669.92 / -18.56 (-2.70%) BMO Capital analyst Ari… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options EQIX Equinix $669.92 / -18.56 (-2.70%) 05/19/22 Equinix highlights latest progress on ESG commitments 03/18/22 Equinix to acquire four Entel data centers for $705M 02/24/22 Equinix names Nicole Collins as Chief Transformation Officer 02/07/22 Equinix opens new IBX data center in Aschheim EQIX Equinix $669.92 / -18.56 (-2.70%) 05/24/22 Stifel Equinix added to 'Select List' on selloff at Stifel 04/29/22 JPMorgan Equinix price target raised to $880 from $860 at JPMorgan 04/25/22 Credit Suisse Equinix price target raised to $714 from $673 at Credit Suisse 04/08/22 Deutsche Bank Equinix price target raised to $785 from $780 at Deutsche Bank EQIX Equinix $669.92 / -18.56 (-2.70%) 04/27/22 Equinix sees FY22 revenue $7.29B-$7.34B, consensus $7.24B 04/27/22 Equinix raises FY22 AFFO view to $28.93-$29.26 from $28.87-$29.20 04/27/22 Equinix sees Q2 revenue $1.81B-$1.83B, consensus $1.79B 04/27/22 Equinix reports Q1 adjusted FFO $7.16, consensus $7.19 06/07/22 BMO Hosted Company Meetings at REITweek EQIX Equinix $669.92 / -18.56 (-2.70%) 02/17/22 Early notable gainers among liquid option names on February 17th
Hot Stocks	Mereo BioPharma to present updated Phase 1b/2 data on Etigilimab and Nivolumab » 18:57 05/26/22 05/26 18:57 05/26/22 18:57 MREO Mereo BioPharma / + Mereo BioPharma announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Events MREO Mereo BioPharma / + 05/17/22 Mereo BioPharma announces appointment of Mullick to board of directors 05/09/22 Mereo BioPharma announces top-line efficacy data from Astraeus Phase 2 trial 04/20/22 Ultragenyx announces first patient dosed in Phase 2/3 study of UX143 03/01/22 Mereo BioPharma announces appointment of Hyland to board of directors 05/31/22 Mereo BioPharma 06/01/22 Mereo BioPharma

Hot Stocks	Affimed to present on three AFM24 clinical trial designs at ASCO 2022 » 18:55 05/26/22 05/26 18:55 05/26/22 18:55 AFMD Affimed $3.15 / -0.02 (-0.63%) Affimed announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate On The Fly Events AFMD Affimed $3.15 / -0.02 (-0.63%) 05/16/22 Affimed presents data on AFM24, AFM28 in poster presentations 05/12/22 Affimed to present preclinical data on cytotoxic activity of AFM28 04/10/22 Affimed provides data updated from ongoing study of AFM13 Precomplexed with cbNK 04/08/22 Affimed says it reached 'safe and well-tolerated' Phase 2 dose in AFM24 study AFMD Affimed $3.15 / -0.02 (-0.63%) 04/11/22 Cantor Fitzgerald Affimed AFM13 + NK combination data exceed expectations, says Cantor Fitzgerald 03/30/22 Piper Sandler Affimed initiated with an Overweight at Piper Sandler 02/23/22 Cantor Fitzgerald Affimed initiated with an Overweight at Cantor Fitzgerald 02/23/22 Cantor Fitzgerald Affimed initiated with an Overweight at Cantor Fitzgerald 13 Apr AFMD Affimed $3.15 / -0.02 (-0.63%) 04/11/22 What You Missed On Wall Street This Morning 04/11/22 Fly Intel: Pre-market Movers 06/01/22 Affimed - AFMD
Hot Stocks	Oncternal Therapeutics presents interim data for Zilovertamab+Ibrutinib at ASCO » 18:51 05/26/22 05/26 18:51 05/26/22 18:51 ONCT Oncternal Therapeutics / + Oncternal Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events ONCT Oncternal Therapeutics / + 04/13/22 Oncternal Therapeutics expects cash runway well into 3Q23 04/13/22 Oncternal Therapeutics deprioritizes development of ONCT-216 01/04/22 Oncternal in pact with FDA for registrational study design for zilovertam in MCL ONCT Oncternal Therapeutics / + 05/10/22 Maxim Oncternal Therapeutics initiated with a Buy at Maxim 02/24/22 BTIG Oncternal Therapeutics initiated with a Buy at BTIG 02/24/22 BTIG Oncternal Therapeutics initiated with a Buy at BTIG ONCT Oncternal Therapeutics / + 05/05/22 Oncternal Therapeutics reports Q1 EPS (20c), consensus (20c) ONCT Oncternal Therapeutics / + 01/05/22 Fly Intel: Pre-market Movers 01/04/22 Fly Intel: After-Hours Movers 06/07/22 2022 ASCO Annual Meeting 06/16/22 Oncternal Therapeutics Inc
Hot Stocks	Puma Biotechnology to present two abstracts on neratinib at ASCO Meeting » 18:49 05/26/22 05/26 18:49 05/26/22 18:49 PBYI Puma Biotechnology $1.95 / +0.035 (+1.83%) Puma Biotechnology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events PBYI Puma Biotechnology $1.95 / +0.035 (+1.83%) 02/15/22 Coherus Biosciences announces Paul Reider as chief commercial officer 01/12/22 Puma Biotechnology's NERLYNX included in NCCN guidelines for breast cancer 12/10/21 Puma Biotechnology presents updates from Phase II SUMMIT trial PBYI Puma Biotechnology $1.95 / +0.035 (+1.83%) 05/06/22 H.C. Wainwright Puma Biotechnology price target lowered to $12 from $14 at H.C. Wainwright 09/28/21 Fly Intel: Top five analyst upgrades 09/28/21 Citi Puma Biotechnology upgraded to Buy after 40% selloff at Citi 09/27/21 Citi Puma Biotechnology upgraded to Buy from Neutral at Citi PBYI Puma Biotechnology $1.95 / +0.035 (+1.83%) 05/05/22 Puma Biotechnology reports Q1 EPS (1c), consensus (17c) 03/03/22 Puma Biotechnology reports Q4 EPS 21c, consensus (9c) PBYI Puma Biotechnology $1.95 / +0.035 (+1.83%) 01/13/22 Fly Intel: Pre-market Movers 06/14/22 Puma Biotechnology, Inc.
Hot Stocks	Invitae to present eight studies at ASCO » 18:48 05/26/22 05/26 18:48 05/26/22 18:48 NVTA Invitae $3.50 / +0.095 (+2.79%) Invitae "announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options NVTA Invitae $3.50 / +0.095 (+2.79%) 05/09/22 NeoGenomics appoints Vishal Sikri as presdent, CCO of Inivata 05/04/22 Cathie Wood's ARK Investment bought 272.5K shares of Invitae today 05/03/22 Allelica enters partnership with Invitae to build ancestry-informed PRS 04/14/22 Invitae falls -7.4% NVTA Invitae $3.50 / +0.095 (+2.79%) 05/04/22 Raymond James Invitae price target lowered to $8.50 from $10.50 at Raymond James 02/28/22 Raymond James Invitae price target lowered to $15 from $36 at Raymond James 11/09/21 Wells Fargo Invitae price target lowered to $25 from $35 at Wells Fargo 10/14/21 Cowen Invitae coverage transferred at Cowen NVTA Invitae $3.50 / +0.095 (+2.79%) 05/03/22 Invitae reports Q1 non-GAAP EPS 78c, consensus (76c) 02/24/22 Invitae sees 2022 revenue $640M, consensus $638.69M 02/24/22 Invitae reports Q4 non-GAAP EPS (81c), consensus (73c) 06/07/22 2022 ASCO Annual Meeting 06/06/22 Invitae Corporation NVTA Invitae $3.50 / +0.095 (+2.79%) 05/03/22 Invitae options imply 14.1% move in share price post-earnings 02/24/22 Invitae options imply 14.1% move in share price post-earnings
Hot Stocks	Arbutus Biopharma to present data from preclinical study of PD-L1 inhibitor » 18:47 05/26/22 05/26 18:47 05/26/22 18:47 ABUS Arbutus Biopharma $2.31 / +0.055 (+2.44%) Arbutus Biopharma's… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options ABUS Arbutus Biopharma $2.31 / +0.055 (+2.44%) 05/05/22 Arbutus Biopharma expects cash to fund operations into Q2 of 2024 05/05/22 Arbutus Biopharma announces upcoming milestones 02/28/22 Artubus, Genevant file patent infringement suit against Moderna 02/28/22 Genevant Sciences, Arbutus file patent infringement suit against Moderna ABUS Arbutus Biopharma $2.31 / +0.055 (+2.44%) 03/14/22 H.C. Wainwright Arbutus Biopharma price target raised to $8.50 from $8 at H.C. Wainwright 03/04/22 Chardan Arbutus Biopharma price target raised to $6 from $5.50 at Chardan 12/29/21 Jefferies Arbutus Biopharma assumed with a Hold at Jefferies 12/13/21 H.C. Wainwright H.C. Wainwright sees Arbutus' $300M-plus licensing deal for AB-729 as low-risk ABUS Arbutus Biopharma $2.31 / +0.055 (+2.44%) 05/05/22 Arbutus Biopharma reports Q1 EPS (11c), consensus (16c) 03/03/22 Arbutus Biopharma reports 2021 EPS (83c), consensus (86c) ABUS Arbutus Biopharma $2.31 / +0.055 (+2.44%) 05/08/22 Moderna seeks to dismiss COVID vaccine patent lawsuit, WSJ reports ABUS Arbutus Biopharma $2.31 / +0.055 (+2.44%) 12/29/21 Wingstop, Akamai initiations among today's top calls on Wall Street 12/01/21 Wall Street in Fives - Must Read Lists for Wednesday 12/01/21 Wall Street in Fives - Must Read Lists at Midday 10/03/22 6th Annual Genetic Medicines Conference ABUS Arbutus Biopharma $2.31 / +0.055 (+2.44%) 12/02/21 Unusually active option classes on open December 2nd 12/01/21 Unusually active option classes on open December 1st

Hot Stocks	Elevation Oncology to present initial Seribantumab data at ASCO » 18:46 05/26/22 05/26 18:46 05/26/22 18:46 ELEV Elevation Oncology $3.35 / -0.62 (-15.64%) Elevation Oncology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events ELEV Elevation Oncology $3.35 / -0.62 (-15.64%) 05/25/22 Elevation Oncology granted FDA Fast Track designation for seribantumab 04/27/22 Elevation Oncology says initial data from Phase 2 CRESTONE study coming at ASCO 03/14/22 Elevation Oncology names David Dornan, Ph.D., as Chief Scientific Officer ELEV Elevation Oncology $3.35 / -0.62 (-15.64%) 05/06/22 Wedbush Elevation Oncology price target lowered to $15 from $21 at Wedbush 03/04/22 Wedbush Elevation Oncology price target lowered to $21 from $27 at Wedbush 12/23/21 Fly Intel: Top five analyst initiations 12/23/21 H.C. Wainwright Elevation Oncology initiated with a Buy at H.C. Wainwright ELEV Elevation Oncology $3.35 / -0.62 (-15.64%) 05/05/22 Elevation Oncology reports Q1 EPS (74c), consensus (50c) 03/03/22 Elevation Oncology reports Q4 EPS ($2.64), consensus (59c) 25 Jun 06/07/22 2022 ASCO Annual Meeting 06/17/22 Elevation Oncology, Inc.
Hot Stocks	PDS Biotechnology announces presentation of Phase 2 data on PDS0101 at ASCO » 18:42 05/26/22 05/26 18:42 05/26/22 18:42 PDSB PDS Biotechnology $4.99 / -0.06 (-1.19%) PDS Biotechnology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events PDSB PDS Biotechnology $4.99 / -0.06 (-1.19%) 05/18/22 PDS Biotechnology appoints Sanjay Zaveri to SVP, business development 04/19/22 PDS Biotechnology receives $1.2M after selling NOL tax benefits 04/08/22 PDS Biotechnology reports inducement grants under Nasdaq listing rule 03/31/22 PDS Biotechnology expects cash to fund operations through end of 2023 PDSB PDS Biotechnology $4.99 / -0.06 (-1.19%) 05/13/22 Alliance Global Partners PDS Biotechnology price target lowered to $16 from $18 at Alliance Global Partners 10/21/21 H.C. Wainwright H.C. Wainwright says PDS Biotechnology temporary hold shouldn't spark concerns 08/12/21 H.C. Wainwright PDS Biotechnology price target lowered to $15 from $20 at H.C. Wainwright 06/28/21 Cantor Fitzgerald PDS Biotechnology initiated with an Overweight at Cantor Fitzgerald PDSB PDS Biotechnology $4.99 / -0.06 (-1.19%) 05/11/22 PDS Biotechnology reports Q1 EPS (32c), consensus (22c) 03/31/22 PDS Biotechnology reports 2021 EPS (66c), consensus (71c) 15 Jun PDSB PDS Biotechnology $4.99 / -0.06 (-1.19%) 18:31 Today Fly Intel: After-Hours Movers 06/07/22 2022 ASCO Annual Meeting 06/15/22 PDS Biotechnology Corporation
Hot Stocks	Gracell to present updated clinical data on GC012F in multiple myeloma » 18:40 05/26/22 05/26 18:40 05/26/22 18:40 GRCL Gracell $3.00 / -0.045 (-1.48%) Gracell Biotechnologies… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events GRCL Gracell $3.00 / -0.045 (-1.48%) 05/12/22 Gracell to present clinical data on GC012F in RRMM and B-NHL at EHA2022 04/28/22 Gracell to present longer-term follow-up clinical data evaluating GC012F at ASCO 02/22/22 Gracell reports advancements of TruUCAR CAR-T cell platform 02/17/22 Gracell doses first patients in clinical trial of lymphoma candidate GC012F GRCL Gracell $3.00 / -0.045 (-1.48%) 04/04/22 BTIG BTIG starts Gracell at Buy, sees stock trading at 'significant discount' 04/04/22 BTIG Gracell initiated with a Buy at BTIG 03/14/22 Piper Sandler Gracell price target lowered to $25 from $40 at Piper Sandler 06/14/21 Piper Sandler Gracell plans to expand GC012F's clinical profile, says Piper Sandler GRCL Gracell $3.00 / -0.045 (-1.48%) 05/16/22 Gracell reports Q1 EPS (RMB0.33) vs. (RMB0.47) last year 03/14/22 Gracell reports Q4 EPS (6c), one estimate (33c) GRCL Gracell $3.00 / -0.045 (-1.48%) 04/04/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/14/22 Fly Intel: Pre-market Movers 06/01/22 China Biotech Day 06/07/22 2022 ASCO Annual Meeting 06/11/22 EHA 2022
Hot Stocks	SpringsWorks Therapeutics presents Nirogacestat Clinical Data at 2022 ASCO » 18:39 05/26/22 05/26 18:39 05/26/22 18:39 SWTX SpringsWorks Therapeutics $30.81 / -1.76 (-5.40%) , GSK GlaxoSmithKline $44.41 / -0.57 (-1.27%) SpringWorks Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SWTX GSK SWTX SpringsWorks Therapeutics $30.81 / -1.76 (-5.40%) 05/24/22 SpringsWorks Therapeutics: Nirogacestat achieved endpoints in Phase 3 DeFi trial 04/19/22 SpringsWorks announces agreeement with Regeneron for nirogacestat 12/10/21 SpringsWorks Therapeutics announces trial collaboration with AbbVie 12/06/21 SpringsWorks Therapeutics doses first patient in Phase 1b/2 nirogacestat study GSK GlaxoSmithKline $44.41 / -0.57 (-1.27%) 04/29/22 SK bioscience, GSK report COVID-19 vaccine candidate meets Phase 3 objectives 04/27/22 GSK expects COVID-19 solutions to contribute similar sales level to 2021 04/27/22 GlaxoSmithKline sees FY Specialty Medicines sales up 10% at CER 04/27/22 GlaxoSmithKline CEO says delivered 'strong' Q1 results SWTX GSK SWTX SpringsWorks Therapeutics $30.81 / -1.76 (-5.40%) 05/24/22 Goldman Sachs SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs 03/01/22 H.C. Wainwright SpringsWorks Therapeutics price target raised to $142 from $137 at H.C. Wainwright 10/27/21 Wedbush Wedbush recommends buying SpringsWorks shares ahead of BLENREP combo data 09/08/21 JPMorgan SpringsWorks price target raised to $105 from $97 at JPMorgan GSK GlaxoSmithKline $44.41 / -0.57 (-1.27%) 05/19/22 Deutsche Bank GlaxoSmithKline price target raised to 1,750 GBp at Deutsche Bank 05/17/22 Roth Capital Ideaya Biosciences price target raised to $46 from $42 at Roth Capital 05/13/22 Jefferies Roche downgraded to Hold from Buy at Jefferies 04/29/22 Barclays GlaxoSmithKline price target raised to 1,800 GBp from 1,775 GBp at Barclays SWTX GSK SWTX SpringsWorks Therapeutics $30.81 / -1.76 (-5.40%) 05/05/22 SpringsWorks Therapeutics reports Q1 EPS ($1.26), consensus ($1.02) 02/24/22 SpringsWorks Therapeutics reports Q4 EPS ($1.15), consensus (88c) GSK GlaxoSmithKline $44.41 / -0.57 (-1.27%) 04/27/22 GlaxoSmithKline reaffirms FY22 sales growth between 5%-7% at CER 04/27/22 GlaxoSmithKline reports Q1 adjusted EPS 32.8p vs. 22.9p last year 04/13/22 GlaxoSmithKline backs FY22 revenue view up 5%-7% at CER, consensus $47.34B 02/25/22 Vir Biotechnology falls 5% after Q4 sales top estimates GSK GSK GlaxoSmithKline $44.41 / -0.57 (-1.27%) 05/25/22 Nestle mulled GSK consumer deal, but dropped idea, Bloomberg reports 05/25/22 Nestle considered GSK consumer deal, but dropped idea, Bloomberg says 03/30/22 DOJ probes network accused of selling counterfeit HIV drugs, WSJ reports 02/06/22 Two big Unilever investors want split or new chair, FT reports SWTX GSK SWTX SpringsWorks Therapeutics $30.81 / -1.76 (-5.40%) 18:31 Today Fly Intel: After-Hours Movers 05/24/22 What You Missed On Wall Street On Tuesday 05/24/22 What You Missed On Wall Street This Morning 05/13/22 Proven algorithm says sell these stocks now GSK GlaxoSmithKline $44.41 / -0.57 (-1.27%) 04/13/22 What You Missed On Wall Street On Wednesday 04/13/22 What You Missed On Wall Street This Morning 04/13/22 Fly Intel: Pre-market Movers 01/31/22 Meet Lyell: Fly exclusive interview with CEO Liz Homans 06/07/22 2022 ASCO Annual Meeting GSK GSK GlaxoSmithKline $44.41 / -0.57 (-1.27%) 05/09/22 GlaxoSmithKline call volume above normal and directionally bullish 03/07/22 GlaxoSmithKline put volume heavy and directionally bearish 01/21/22 GlaxoSmithKline call volume above normal and directionally bullish 12/15/21 GlaxoSmithKline call volume above normal and directionally bullish
Hot Stocks	Alaunos Therapeutics to present data on TCR-T Library Phase 1/2 trial » 18:36 05/26/22 05/26 18:36 05/26/22 18:36 TCRT Alaunos Therapeutics / + Alaunos Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options TCRT Alaunos Therapeutics / + 05/16/22 Alaunos Therapeutics expects cash to fund operations into 2Q23 05/02/22 Alaunos Therapeutics doses first patient in TCR-T Library Phase 1/2 trial 03/30/22 Alaunos Therapeutics expects cash to fund operations into 2Q23 01/26/22 Ziopharm highlights operational updates, rebrands to Alaunos Therapeutics TCRT Alaunos Therapeutics / + 05/04/22 Wells Fargo Wells Fargo upgrades Alaunos Therapeutics to Overweight with $3 price target 05/04/22 Wells Fargo Alaunos upgraded to Overweight from Equal Weight at Wells Fargo TCRT Alaunos Therapeutics / + 05/16/22 Alaunos Therapeutics reports Q1 EPS (5c), consensus (7c) 03/30/22 Alaunos Therapeutics reports Q4 EPS (5c), consensus (8c) 06/13/22 Alaunos Therapeutics Inc TCRT Alaunos Therapeutics / + 03/09/22 ZIOPHARM Oncology Inc. options imply 13.4% move in share price post-earnings 01/27/22 One new option listing and one option delisting on January 27th

Events

Earnings calls, analyst events, roadshows and more

FANH
Today at 21:00

Fanhua - FANH Conference Calls
LIZI
Today at 21:00

Lizhi - LIZI Conference Calls
CWBC
Today at 21:30

Community West Bancshares Firm Sponsored Meetings

4015 Via Laguna, Santa Barbara, CA
Tomorrow at 00:00

Annual Neuro & Ophthalmology Virtual Investor Conference Conferences

Virtual Conference
Tomorrow at 00:00

TechNet Conference Asia Pacific 2022 Conferences

Virtual Conference
EXPO
Tomorrow at 00:00

Exponent Firm Sponsored Meetings

Chicago, IL
CYRX
Tomorrow at 00:00

Cryoport Firm Sponsored Meetings

Irvine, CA
IART
Tomorrow at 00:00

Integra LifeSciences Firm Sponsored Meetings

Los Angeles, CA
SABR
Tomorrow at 00:00

Sabre Firm Sponsored Meetings

West Coast
Tomorrow at 00:00

Metals & Mining Industry Meetings

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	KDNY X KDNY Chinook Therapeutics Spot Secondary Managers: SVB Leerink, Cantor Fitzgerald, William Blair & Wedbush Priced at: $14.00 6.429M Shares
Wed	ADC X ADC Agree Realty Spot Secondary Managers: Citi & Wells Fargo Priced at: $68.65 5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	ACB X ACB Aurora Cannabis Spot Secondary Managers: Canaccord & BMO Capital Priced at: $2.45 51.1M Shares
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	CLIR X CLIR ClearSign Combustion Spot Secondary Managers: Newbridge Securities $1.31
Fri	No deals

View All Syndicate Announcements »

Navios Maritime Partners to acquire four newbuilding vessels for $58.5M each

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access